Patients with end-stage pancreatic ductal adenocarcinoma achieved unprecedented survival rates after being treated with the Engeneic dream vector nanocells, with 88% of patients doubling the historical survival rates, Engeneic Ltd. co-CEO Jennifer MacDiarmid told BioWorld.
Proteoglycan glypican-1 (GPC1) is a tumor-associated antigen that is highly expressed in tumor tissues from patients with pancreatic ductal adenocarcinoma (PDAC), while its expression is very low on benign neoplastic lesions, chronic pancreatitis and normal adult pancreatic tissue. Researchers from Centro Di Riferimento Oncologico (CRO Aviano) and L'Università degli studi di Trieste have reported the development and preclinical characterization of AT-101, a novel complement-fixing IgM antibody targeting GPC1, as a potential immunotherapy candidate for the treatment of PDAC.
Patients with end-stage pancreatic ductal adenocarcinoma achieved unprecedented survival rates after being treated with the Engeneic dream vector nanocells, with 88% of patients doubling the historical survival rates, Engeneic Ltd. co-CEO Jennifer MacDiarmid told BioWorld.
Abbisko Therapeutics Co. Ltd. has received clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China of ABSK-051, a novel small-molecule CD73 inhibitor, for advanced solid tumors.
Pancreatic ductal adenocarcinoma (PDAC) is an exocrine pancreatic cancer with a poor prognosis and limited treatment options. There is a strong demand for new treatment strategies to overcome these challenges.
Researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College reported on the development of a novel EDB-FN-targeted Gd-based contrast agent, named EDB-Gd-DOTA-Cy7, for imaging and treatment planning of pancreatic ductal adenocarcinoma (PDAC).
The traps that neutrophils develop against microorganisms also hold T cells and prevent the success of immunotherapy in pancreatic cancer. To free the immune system from itself, scientists at the Istituto Oncologico Veneto in Italy made a key that unlocked this sticky dungeon from an antibody against arginase-1 (ARG1), an enzyme also present in the trap.
Previous studies have demonstrated that increased expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) correlated with poor prognosis in patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC). In the current study, a research team at the University of Rochester Medical Center aimed to assess the impact of blocking GM-CSFR signaling in CCA and PDAC.
Tumors have a lower interstitial pH compared to healthy tissues, with tumor acidity having emerged as a driver of tumor progression as it can lead to tumor immune evasion. Solute carrier family 4 member 4 (SLC4A4), which encodes a sodium bicarbonate cotransporter involved in pH regulation and homeostasis in normal tissue, was the focus of studies in pancreatic cancer resistance in in vivo preclinical models. Researchers tested the impact of Slc4a4 deletion in cancer cells on tumor growth, anticancer immunity and response to immunotherapy in murine models of pancreatic ductal adenocarcinoma (PDAC).
